Biogen adds real-world test for Aduhelm to its confirmatory trialBiogen and partner Eisai have said they will run a large-scale observational study of Alzheimer’s drug Aduhelm in Share XBiogen adds real-world test for Aduhelm to its confirmatory trialhttps://pharmaphorum.com/news/biogen-adds-real-world-test-for-aduhelm-to-its-confirmatory-trial/
Biogen bites back at critics of Aduhelm after drug’s slow startBiogen has reported $2m in sales for newly-launched Alzheimer’s therapy Aduhelm that came in below its expectations, prompting Share XBiogen bites back at critics of Aduhelm after drug’s slow starthttps://pharmaphorum.com/news/biogen-bites-back-at-critics-of-aduhelm-after-drugs-slow-start/
FDA staffers defend Aduhelm approval in JAMA editorialThree FDA figures at the centre of the fallout over the approval Biogen and Eisai’s Alzheimer’s disease therapy Share XFDA staffers defend Aduhelm approval in JAMA editorialhttps://pharmaphorum.com/news/fda-staffers-defend-aduhelm-approval-in-jama-editorial/
Biogen builds MS pipeline via $125m deal with China’s InnoCareBiogen has moved to shore up its besieged multiple sclerosis franchise by licensing a BTK inhibitor from Chinese Share XBiogen builds MS pipeline via $125m deal with China’s InnoCarehttps://pharmaphorum.com/news/biogen-builds-ms-pipeline-via-125m-deal-with-chinas-innocare/
US starts review of Aduhelm coverage amid fears of Medicare hitThe US government has started a review of how Biogen and Eisai’s pricey new Alzheimer’s disease therapy Aduhelm Share XUS starts review of Aduhelm coverage amid fears of Medicare hithttps://pharmaphorum.com/news/us-starts-review-of-aduhelm-coverage-amid-fears-of-medicare-hit/
Aduhelm approval controversy dials up as FDA seeks probeIn another twist to the Aduhelm approval tale, FDA’s Janet Woodcock has called for an independent investigation into Share XAduhelm approval controversy dials up as FDA seeks probehttps://pharmaphorum.com/news/aduhelm-approval-controversy-dials-up-as-fda-seeks-probe/
FDA whittles back Aduhelm approval amid concern over broad labelOne of the criticisms levelled at the FDA over its approval of Biogen and Eisai’s Alzheimer’s disease drug Share XFDA whittles back Aduhelm approval amid concern over broad labelhttps://pharmaphorum.com/news/fda-whittles-back-aduhelm-approval-amid-concern-over-broad-label/
ICER revises its view of Aduhelm’s price – but not by muchThe Institute for Clinical and Economic Review (ICER) was very damning of Biogen’s new Alzheimer’s disease therapy Aduhelm Share XICER revises its view of Aduhelm’s price – but not by muchhttps://pharmaphorum.com/news/icer-revises-its-view-of-aduhelms-price-but-not-by-much/
Amid outcry over Aduhelm price, Biogen says it may consider ‘adjustment’Biogen has hinted that it may consider altering the price of its controversially-approved Alzheimer’s therapy Aduhelm – but Share XAmid outcry over Aduhelm price, Biogen says it may consider ‘adjustment’https://pharmaphorum.com/news/amid-outcry-over-aduhelm-price-biogen-says-it-may-consider-adjustment/
